Best Unity Stoakes Podcasts (2025)

1
FH25: The intersection of tech, science & design with Unity Stoakes 10:11

Play Pause

6d ago10:11

10:11

This year marks the 10th anniversary of Frontiers Health. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Unity Stoakes, president and co-founder of Startup Health and Advisory Board Member at The NeuroTech Collider Lab, University of California, Berkeley. Stoakes has spent 3…

1
FH25: The art of connection at Frontiers Health with Aline Noizet 11:04

8h ago11:04

11:04

Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Aline Noizet, founder of Digital Health Connector – a phrase that she says…

1
Policy in Focus: Trump’s Most Favoured Nations drug pricing scheme – with Alice Valder Curran 35:41

12h ago35:41

35:41

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more …

1
FH25: Exploring the intersection of patients, HCPs, and technology with Denise Silber 12:54

3h ago12:54

12:54

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0. Having spent more than two decades working at the intersection…

1
Investing with Purpose: A Conversation with Vishal Vasishth of Obvious Ventures

10d ago

—

In this special episode of StartUp Health NOW, recorded in front of a live virtual audience of StartUp Health community members, Unity Stoakes sits down with Vishal Vasishth, Co-founder & Managing Director of Obvious Ventures. Listeners get to hear not only Vishal’s insights on purpose-driven investing but also questions from community members who …

1
Doing good in people’s lives: Amy Burroughs discusses CML 10:39

3h ago10:39

10:39

Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatm…

1
FH25: Individual centric investing with Steve Seuntjens 9:12

7d ago9:12

9:12

In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital. Seuntjens has long been focused on investing in innovation that puts the individual at the centre of health. For him, building companies is never easy – but it becomes meaningful w…

1
Pharma and health advertising: Brian Coane on the necessity of humour 17:17

4d ago17:17

17:17

When it comes to breaking down barriers, humour is vitally important, helping to do away with stigma when it comes – in particular – to pharma and health advertising. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brian Coane, health partner at creative agency Leith, who talks sensitivity, maximum impact, and overcoming the fe…

1
Why We Opened the StartUp Health Network to the Ecosystem 38:10

4d ago38:10

38:10

An insider interview with StartUp Health co-founder Unity Stoakes on our new membership that invites the world’s leading investors, buyers, industry experts, and policymakers to our exclusive member community dedicated to health innovation and achieving health moonshots. We flipped the script. In this special episode of StartUp Health NOW, our regu…

1
The glimmer of opportunity behind the storm: Ali Pashazadeh talks biotech investment 26:11

4d ago26:11

26:11

Biotech finance has encountered what can arguably be termed the worst perfect storm in its history, and private investment in biopharma is in the midst of the longest drought. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, a strategic and financial advisory …

1
Changing the drug development treatment paradigm: Hilary Eaton on AI and LLMs 23:33

7d ago23:33

23:33

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Hilary Eaton, a rare disease advocate and chief business officer at Profluent about AI-first protein design and its part in accelerating biomedicine. Eaton discusses her advocacy, gene editing, and how real-world evidence shows that AI scaling laws – which predict model performanc…

1
Increasing trial efficiency: Adityo Prakash talks small datasets, real-world scenarios, and organoids 17:01

12d ago17:01

17:01

Characterising the behaviour of drugs in humans has historically required extensive clinical trials at considerable time and cost. So, any lab-derived early insight into how drugs will behave in human patients can make drug trials vastly more efficient. In this episode, the pharmaphorum podcast welcomes Adityo Prakash, founder and CEO of Verseon, a…

1
FH25: Ten years at the forefront of health innovation, with Kristin Milburn 13:00

13d ago13:00

13:00

This November marks a major milestone for health innovation as Frontiers Health celebrates its 10th anniversary. To mark the occasion, pharmaphorum is proud to launch a special limited-edition podcast series, bringing you conversations with the people who’ve helped define the conference over the years – and those driving the next wave of innovation…

1
Supercharging Alzheimer’s Research: Gates Ventures Backs a Million-Dollar AI Initiative 29:14

1M ago29:14

29:14

Unlocking Innovation: The Alzheimer’s Insights AI Prize and Its Impact on Healthcare There are currently more than 55 million people worldwide living with Alzheimer’s disease and related dementias. Recent breakthroughs in new treatments and diagnostics provide hope, but there is potential to accelerate the pace of discovery and development. Last ye…

1
MAPs, EAPs, and patient access: Suzanne Aitken on the challenges for pharma 15:57

29d ago15:57

15:57

Managed Access Programs (or MAPs) enable mechanisms for patients with unmet medical needs to get access to new medications outside of the clinical trial setting and well before marketing authorisation and reimbursement in a patient's country. Also referred to as Expanded Access Programs and Early Access Programs, these programs are not limited to t…

1
The Future of Health Fundraising: How Ribon Is Revolutionizing Philanthropy 22:29

1M ago22:29

22:29

Transforming Healthcare Fundraising: A Revolutionary Approach In this episode of StartUp Health NOW, discover how Rafael Rodeiro, CEO & Founder of Ribon Health, is revolutionizing nonprofit healthcare fundraising through an innovative platform that’s changing the game. From a modest start in Brasilia to developing a groundbreaking “reverse matching…

1
Weighing in on GLP-1 drugs 35:42

21d ago35:42

35:42

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the drugs and where it could go next to the cultural and societal implications of this highly effective treatment for diabetes, weight loss, and potentially much more. On today’s podcast editor-in-chief Jonah Comstock and Deep Dive e…

1
The TechBio way: Brendan Frey talks genomics, AI, and RNA 26:34

1M ago26:34

26:34

Overall, the pharmaceutical industry is moving away from an approach where AI is task-driven, narrowly focused on a single, isolated problem. Instead, companies are embracing foundation models which, trained on very large and broad datasets, are versatile, and capable of tackling a range of complex challenges simultaneously. In a new pharmaphorum p…

1
Advancing the frontier of cancer diagnostics: Post-ASCO with Eric Matthews 8:41

28d ago8:41

8:41

Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to realise the potential of precision medicine and help improve the lives of as many people as possible. In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life Sciences, about advancing the frontier of …

1
Compliance baked into the design core: On AI in life sciences with Florian Schnappauf 19:18

1M ago19:18

19:18

When it comes to artificial intelligence, the tables are turning and there is a shift in considering it a hype to understanding that AI is a real necessity. And 2025 is becoming a turning point wherein practical, embedded AI begins to scale. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Florian Schnappauf, VP, enterprise comm…

1
Caregiving Reimagined: How CAREgivers Insight Empowers the Circle of Care 31:28

2M ago31:28

31:28

In this episode of StartUp Health NOW, Unity Stoakes, President & Co-founder of StartUp Health, speaks with Christopher Jue, CEO & Co-founder of CAREgivers Insight, a leading member of our Caregiving Health Moonshot Community. Christopher, a serial entrepreneur with a personal connection to caregiving, shares the story behind his company’s mission …

1
Putting patients and their families first: Dr Corina Dutcus, post-ASCO 2025 18:40

2M ago18:40

18:40

At ASCO 2025, Eisai presented data from its oncology portfolio, including in hepatocellular carcinoma and endometrial cancer. In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the company’s continued commitm…

1
Enhancing anti-tumour activity: A post-ASCO conversation with Dan Schmitt 28:19

1M ago28:19

28:19

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases. At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resi…

1
Redefining the Future of Melanoma Treatment: Scancell's Bold Step Forward 19:05

2M ago19:05

19:05

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks wi…

1
Why Datavant bought Aetion, and what comes next, with Arnaub Chatterjee 30:40

2M ago30:40

30:40

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the real-world data space. Now that the acquisition has closed, the pharmaphorum podcast welcomes Arnaub Chatterjee, president and general manager of life sciences at Datavant, to discuss what that integration will look like -- and what …

1
Post-ASCO 25: Pamela Tenaerts on CGTs and digital-first long-term follow-up 21:24

2M ago21:24

21:24

When it comes to CGTs, long-term follow-up care is an issue that makes patient access to these novel investigative treatments extremely limited, given the 15 years that patients must still engage with the trial after receiving the medication. In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chi…

1
Immune mediation, B-cell depletion, and female leadership – with Aoife Brennan 25:02

2M ago25:02

25:02

In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases. Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, and Brennan talks about the potential of B-cell depletion therapies, as well as the challenges and opportunities in developing …

1
Ben Sidders on integrating causality in AI for R&D success 15:26

2M ago15:26

15:26

For AI to truly revolutionise drug discovery, it must move beyond pattern recognition and predictive analytics to include causality, which is essential for technical and regulatory success in drug discovery. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ben Sidders, chief scientific officer at Biorelate, a company leveraging …

1
On nuclear medicine and oncology, SHINE technologies 25:32

2M ago25:32

25:32

Radiopharmaceutical therapy has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies, such as in oncology. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Greg Piefer, founder and CEO of SHINE Technologies, a nuclear fusion company mastering more immediate applicatio…

1
Unicorns, AI, and the future of health: Highlights from HLTH Europe 2025 1:04:16

2M ago1:04:16

1:04:16

The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands today – and where it’s headed next. Amid economic uncertainty and shifting regulatory priorities, pharma, health tech, and care delivery are all racing …

1
On patient-centric treatment decisions and the value of quantitative methodologies, in conversation with Marc Buyse 16:33

2M ago16:33

16:33

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' perspective in any treatment decision. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, about his recent work as one of the editors of – …

1
Maximising value by uniting the digital backbone: On a new Novo Nordisk and Veeva partnership 13:40

3M ago13:40

13:40

At this year’s Veeva R&D and Quality Summit, it was revealed that Novo Nordisk and Veeva have entered into a new partnership for clinical development. In this episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Stephanie Bova, chief digital officer at Novo Nordisk, and Rik van Mol, SVP R&D and Quality at Veeva, about the partn…

1
Collaborative Innovations: Navigating Digital Health Fundraising with Lee Shapiro of 7wire Ventures 56:19

3M ago56:19

56:19

Healthcare Investment Landscape: Navigating Challenges and Opportunities On this episode of StartUp Health NOW, dive into a compelling conversation with Lee Shapiro, managing partner of 7wire Ventures, as he unravels the complexities of digital health investment in today’s challenging market. Discover how successful healthcare startups are adapting…

1
The changing landscape of drug clinical assessment: Tommy Bramley on the JCA 18:11

3M ago18:11

18:11

The JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all available clinical evidence for new drugs. Rolled out in stages, starting with oncology drugs and advanced therapy medicinal products this year, it will be fully implemented by 2030. In a new pharmaphorum…

1
Precision, speed, impact: Evolving mass spectrometry for medical science 19:22

3M ago19:22

19:22

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly medical science. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Melissa Sherman, CEO of MOBILion Systems, a company pioneering next-generation separation science, by innovating best-in-class instruments that …

1
IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer 14:14

3M ago14:14

14:14

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company’s oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic On…

1
Treating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy 18:37

3M ago18:37

18:37

Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS The…

1
Feeding Health Equity: How EntreVita Is Using AI to Bring Personalized Nutrition to the People Who Need It Most

4M ago

—

From Personal Tragedy to Transformation: Cory Mitchell’s Food as Medicine Mission with EntreVita In this powerful episode of StartUp Health NOW, Unity Stoakes sits down with Cory Mitchell, D.Bioethics, CEO & Founder of EntreVita and a founding member of StartUp Health’s Food as Medicine Health Moonshot Community. Cory shares a deeply personal and i…

1
Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treatment with Tibsovo & Voranigo 9:25

4M ago9:25

9:25

At ASCO 2025, Servier presented data in the IDH-mutated cancer space. Onsite at McCormick Place in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Becky Martin, chief US medical at Servier about the key data from the company’s Tibsovo and Voranigo programmes, as well as the implications for patients and the wider themes of the Congress t…

1
Where innovation meets collaboration: Live from Manchester’s City labs 4.0 38:15

4M ago38:15

38:15

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors. Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built…

1
Live from ASCO 2025: Boehringer Ingelheim on unmet needs and oncology innovation 9:57

4M ago9:57

9:57

Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative therapies for various cancers. In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head of oncology at Boehringer Ingelheim, for a discussio…

1
Bringing patients to research centres: Using AI to bring efficiencies forward 19:07

4M ago19:07

19:07

Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI. Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, la…

1
The need for a science-first mindset: The vaccine landscape today 19:34

4M ago19:34

19:34

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and diseases like whooping cough and measles have seen a worrying resurgence due to anti-vaxxers. And not just in the US. In a new pharmaphorum podcast, Rebecca Catterick, General Manager for Vaccines, UK & Ireland, at Sanofi, di…